Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 12 14 69
Malignant Mesothelioma of Pleura 12
Pleural Malignant Mesothelioma 52

Classifications:



External Ids:

Disease Ontology 12 DOID:7474
ICD10 33 C45.0
NCIt 47 C7376
UMLS 69 C0812413

Summaries for Malignant Pleural Mesothelioma

Disease Ontology : 12 A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to epithelioid sarcoma and lung cancer, and has symptoms including chest pain, dyspnea and fatigue. An important gene associated with Malignant Pleural Mesothelioma is SPP1 (Secreted Phosphoprotein 1), and among its related pathways/superpathways are Pathways in cancer and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Alimta and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and endothelial, and related phenotypes are cellular and cardiovascular system

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
id Related Disease Score Top Affiliating Genes
1 epithelioid sarcoma 30.1 MUC1 WT1
2 lung cancer 28.6 BIRC5 CDH2 CDKN2A EGFR MET NKX2-1
3 mesothelioma, somatic 26.5 CALB2 CDH2 CDKN2A CEACAM3 LINC01194 MET
4 pulmonary artery choriocarcinoma 10.8 CDKN2A WT1
5 thymus lipoma 10.8 CALB2 WT1
6 testis seminoma 10.7 CALB2 CDKN2A
7 iris spindle cell melanoma 10.7 CALB2 MUC1
8 subglottis verrucous carcinoma 10.7 EGFR MUC1
9 exotropia 10.6 MUC1 WT1
10 malignant giant cell tumor of soft parts 10.6 CDKN2A EGFR
11 ovary neuroendocrine neoplasm 10.6 CALB2 MUC1 WT1
12 pancreatic ductal carcinoma 10.5 CALB2 MUC1 WT1
13 dental caries 10.5 MSLN MUC1 WT1
14 nasal cavity disease 10.5 MSLN MUC1 WT1
15 fibrous meningioma 10.5 CDKN2A WT1
16 organic mood syndrome 10.5 EGFR PDPN
17 estrogen-receptor negative breast cancer 10.5 CDKN2A EGFR MUC1
18 pulmonary subvalvular stenosis 10.5 BIRC5 EGFR MET
19 cerebrum cancer 10.5 MUC1 SPP1 WT1
20 cleft lip palate dysmorphism kumar type 10.5 BAP1 EGFR MET
21 hyperandrogenism 10.5 CALB2 MSLN THBD
22 mitochondrial myopathy with lactic acidosis 10.5 MET MUC1 SPP1
23 superior vena cava leiomyosarcoma 10.5 CALB2 THBD
24 mucinous tubular and spindle renal cell carcinoma 10.5 BIRC5 MSLN MUC1
25 pancreatic somatostatinoma 10.4 CDKN2A EGFR MSLN MUC1
26 trachea squamous cell carcinoma 10.4 CDKN2A EGFR MSLN MUC1
27 bladder urachal squamous cell carcinoma 10.4 CDKN2A EGFR MUC1
28 sphenoid sinus squamous cell carcinoma 10.4 CALB2 NKX2-1 THBD
29 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.4 BIRC5 CDKN2A EGFR MUC1
30 paroxysmal nocturnal hemoglobinuria 10.4 CDKN2A EGFR MSLN MUC1
31 testicular trophoblastic tumor 10.4 CALB2 MUC1
32 urethral villous adenoma 10.4 CALB2 NKX2-1 THBD
33 non-distal trisomy 10q 10.4 EGFR MET NKX2-1
34 avian influenza 10.4 CALB2 THBD WT1
35 spermatogenic failure 13 10.4 CALB2 MET MUC1
36 perivascular epithelioid cell tumor 10.4 CALB2 THBD WT1
37 mixed type thymoma 10.4 CALB2 EGFR MUC1 NKX2-1
38 cecum adenocarcinoma 10.4 CDKN2A EGFR MUC1 NKX2-1
39 papillary meningioma of the cerebellum 10.4 PDPN WT1
40 chronic neutrophilic leukemia 10.4 CALB2 CDKN2A MUC1 NKX2-1
41 acute porphyria 10.4 CDKN2A EGFR MUC1
42 oral antidiabetic drugs toxicity or dose selection 10.4 BIRC5 CALB2 PDPN
43 ductal carcinoma in situ 10.3 CDKN2A EGFR PDPN
44 gastrointestinal system cancer 10.3 MET MUC1 NKX2-1
45 gallbladder cancer 10.3 CDKN2A EGFR MET TYMS
46 sarcomatoid squamous cell skin carcinoma 10.3 CDKN2A MET
47 mesenteric vascular occlusion 10.3 CALB2 PDPN WT1
48 dextrocardia with situs inversus 10.3 MUC1 THBD WT1
49 granulomatous orchitis 10.3 EGFR MUC1 NKX2-1
50 malignant peritoneal solitary fibrous tumor 10.3 CALB2 MSLN THBD WT1

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to Malignant Pleural Mesothelioma

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:


chest pain, dyspnea, fatigue, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.31 NKX2-1 PPP1R15A SPP1 THBD TXN WT1
2 cardiovascular system MP:0005385 10.25 BAP1 CDH2 CDKN2A EGFR MET NKX2-1
3 growth/size/body region MP:0005378 10.21 BAP1 CDH2 CDKN2A EGFR MET NKX2-1
4 homeostasis/metabolism MP:0005376 10.18 PDPN SPP1 THBD WT1 XIAP NKX2-1
5 mortality/aging MP:0010768 10.17 BAP1 BIRC5 CDH2 CDKN2A EGFR MET
6 embryo MP:0005380 10.11 BAP1 BIRC5 CDH2 CDKN2A EGFR MET
7 immune system MP:0005387 10.11 BAP1 BIRC5 CDKN2A EGFR MET PDPN
8 digestive/alimentary MP:0005381 10.02 BAP1 CDKN2A EGFR MET NKX2-1 PDPN
9 muscle MP:0005369 9.91 BAP1 CDH2 CDKN2A EGFR MET PDPN
10 neoplasm MP:0002006 9.7 BAP1 CDKN2A EGFR MET NKX2-1 SPP1
11 normal MP:0002873 9.65 MSLN NKX2-1 PPP1R15A THBD WT1 XIAP
12 respiratory system MP:0005388 9.28 BAP1 CDKN2A EGFR MET NKX2-1 PDPN

Drugs & Therapeutics for Malignant Pleural Mesothelioma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Alimta 17 46 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
4
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 5460373 44475014
7
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
8
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
9
Vorinostat Approved, Investigational Phase 3,Phase 1,Phase 2 149647-78-9 5311
10
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
11
Raltitrexed Approved, Investigational Phase 3,Phase 1,Phase 2 112887-68-0 104758
12
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 1 216974-75-3
13
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
14
nivolumab Approved Phase 3,Phase 2 946414-94-4
15
Nintedanib Approved Phase 3,Phase 2 656247-17-5 56843413
16
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
18
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
19
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
20
Doxil Approved June 1999 Phase 3,Phase 2 31703
21 Ranpirnase Investigational Phase 3 196488-72-9
22 Analgesics Phase 3,Phase 2,Phase 1
23 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
25 Antiemetics Phase 3,Phase 2,Phase 1
26 Topoisomerase Inhibitors Phase 3,Phase 2
27 Antimitotic Agents Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
30 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
31 Vitamin B Complex Phase 3,Phase 2,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Vitamin B 12 Phase 2, Phase 3
35 Vitamins Phase 2, Phase 3
36 Autonomic Agents Phase 3,Phase 2,Phase 1
37 BB 1101 Phase 3,Phase 2,Phase 1
38 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
39 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
40 Micronutrients Phase 3,Phase 2
41 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
42 Trace Elements Phase 3,Phase 2
43 Anti-Infective Agents Phase 3,Phase 2,Phase 1
44 Antiviral Agents Phase 3,Phase 2,Phase 1
45 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
46 Histone Deacetylase Inhibitors Phase 3,Phase 2,Phase 1
47 Alkylating Agents Phase 3,Phase 2,Phase 1
48 Mitomycins Phase 3
49 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
50 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 194)

id Name Status NCT ID Phase Drugs
1 NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed Unknown status NCT01098266 Phase 3 NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
2 PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma Unknown status NCT01604005 Phase 3
3 ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
4 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1) Completed NCT00128102 Phase 3 vorinostat;Placebo
5 Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00075699 Phase 3 cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
6 Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery Completed NCT00005636 Phase 3 cisplatin;pemetrexed disodium
7 Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura Completed NCT00004920 Phase 3 cisplatin;raltitrexed
8 A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Completed NCT00190762 Phase 3 Pemetrexed
9 Mesothelioma Avastin Plus Pemetrexed-cisplatin Study Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
10 Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2 Completed NCT01836575 Phase 3 Pemetrexed;Carboplatin
11 Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma Completed NCT00821860 Phase 3
12 Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin Recruiting NCT02709512 Phase 2, Phase 3 ADI-PEG 20 plus Pem Cis
13 Nintedanib (BIBF 1120) in Mesothelioma Recruiting NCT01907100 Phase 3 Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
14 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients Recruiting NCT02899299 Phase 3 Pemetrexed;Cisplatin;Carboplatin
15 PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma Not yet recruiting NCT02991482 Phase 3 Pembrolizumab;Gemcitabine;Vinorelbine
16 A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma Unknown status NCT01279967 Phase 2 ADI-PEG 20
17 Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma Unknown status NCT00886028 Phase 2 Liposomal doxorubicin;Cisplatin
18 Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Unknown status NCT00859495 Phase 2 Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
19 Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma Unknown status NCT00354393 Phase 2 cisplatin;methotrexate;vinorelbine ditartrate
20 Four Versus Six Cycles of Pemetrexed/Platinum for MPM Unknown status NCT02497053 Phase 2 pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
21 A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma Unknown status NCT01569919 Phase 2 Pemetrexed;Cisplatin;Dexamethasone
22 Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
23 Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma Unknown status NCT00859469 Phase 2 Oxaliplatin/Gemcitabine
24 Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00386815 Phase 2 pemetrexed;cisplatin
25 Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. Completed NCT01721018 Phase 1, Phase 2
26 Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma Completed NCT00484276 Phase 2 NGR-hTNF
27 Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma Completed NCT00272558 Phase 2 Carboplatin and Vinorelbine
28 Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity Completed NCT01024946 Phase 2 everolimus
29 Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment Completed NCT01243632 Phase 2 Prolonged 6-hr infusion of gemcitabine
30 A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma Completed NCT01486368 Phase 2 PF-03446962
31 Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma. Completed NCT02004028 Phase 2 VS-6063
32 Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II) Completed NCT00700336 Phase 1, Phase 2 pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
33 Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma Completed NCT01112293 Phase 2 GC1008
34 Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy Completed NCT01265433 Phase 2
35 Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Completed NCT00251550 Phase 1, Phase 2 Pemetrexed;Cisplatin
36 Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00459862 Phase 2 pazopanib hydrochloride
37 Bortezomib in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00513877 Phase 2 bortezomib
38 S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Completed NCT00243074 Phase 2 cediranib maleate
39 Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00227630 Phase 2 cisplatin;pemetrexed disodium
40 Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00392444 Phase 2 sunitinib malate
41 An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma Completed NCT00738582 Phase 2 MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
42 Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma Completed NCT00407459 Phase 2 Bevacizumab, Pemetrexed, Carboplatin
43 Nivolumab in Patients With Recurrent Malignant Mesothelioma Completed NCT02497508 Phase 2 nivolumab
44 Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma Completed NCT00004033 Phase 2 liposomal NDDP
45 A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma. Completed NCT00996567 Phase 2 Cetuximab (Erbitux)
46 S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery Completed NCT00770120 Phase 2 everolimus
47 Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma Completed NCT00101283 Phase 2 pemetrexed disodium;gemcitabine hydrochloride;carboplatin
48 Isolated Thoracic Perfusion (ITP-F) for MPM Completed NCT02467426 Phase 2 Chemotherapy
49 Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Completed NCT00165516 Phase 2 Cisplatin;Sodium Thiosulfate
50 Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma Completed NCT01211275 Phase 1, Phase 2 chemotherapy

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

39
Lung, T Cells, Endothelial, Testes, Liver, Thymus, Bone

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 809)
id Title Authors Year
1
Diagnostic Imaging and workup of Malignant Pleural Mesothelioma. ( 28845826 )
2017
2
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. ( 28870611 )
2017
3
Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment. ( 28051015 )
2017
4
National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. ( 28843362 )
2017
5
The value of delayed phase enhanced imaging in malignant pleural mesothelioma. ( 28932538 )
2017
6
Malignant pleural mesothelioma - Pleural cavity irradiation after decortication with helical tomotherapy. ( 28831280 )
2017
7
Elevated aspartate aminotransferase and monocyte counts predict unfavorable prognosis in patients with malignant pleural mesothelioma. ( 27881012 )
2017
8
BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. ( 27771374 )
2017
9
Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : AA propensity score matching of the SEER database. ( 28044200 )
2017
10
Pathological complete response in malignant pleural mesothelioma patients following induction chemotherapy: Predictive factors and outcomes. ( 28838403 )
2017
11
Asbestos fibres detected by scanning electron microscopy in the gallbladder of patients with malignant pleural mesothelioma (MPM). ( 28066892 )
2017
12
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study. ( 28757678 )
2017
13
Prognostic and predictive role of [(18) F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy. ( 28941158 )
2017
14
Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis. ( 28915685 )
2017
15
Influence of Pleurectomy and Decortication in Health-Related Quality of Life Among Patients with Malignant Pleural Mesothelioma. ( 28948332 )
2017
16
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma. ( 28027772 )
2017
17
Pseudoprogression associated with clinical deterioration and worsening quality of life in malignant pleural mesothelioma. ( 28919393 )
2017
18
The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. ( 28859932 )
2017
19
Open access phone triage for veterans with suspected malignant pleural mesothelioma. ( 27979465 )
2017
20
Near-Infrared Intraoperative Imaging Can Successfully Identify Malignant Pleural Mesothelioma After Neoadjuvant Chemotherapy. ( 28856921 )
2017
21
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). ( 28862644 )
2017
22
New Keywords in the Treatment of Malignant Pleural Mesothelioma. ( 28935312 )
2017
23
Percutaneous Cryoablation for the Treatment of Recurrent Malignant Pleural Mesothelioma: Safety, Early-Term Efficacy, and Predictors of Local Recurrence. ( 27979596 )
2017
24
Prognostic value of pretreatment volume-based quantitative (18)F-FDG PET/CT parameters in patients with malignant pleural mesothelioma. ( 28027744 )
2017
25
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. ( 28892431 )
2017
26
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib. ( 28838714 )
2017
27
Radiotherapy for the treatment of malignant pleural mesothelioma. ( 28884702 )
2017
28
Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response ( 28843224 )
2017
29
Clinical staging of malignant pleural mesothelioma: current perspectives. ( 28860886 )
2017
30
Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells. ( 28476806 )
2017
31
MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma. ( 28918032 )
2017
32
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. ( 28197626 )
2017
33
Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. ( 27009350 )
2016
34
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts. ( 27594045 )
2016
35
Malignant pleural mesothelioma in a young adult with no known exposure to asbestos. ( 27156205 )
2016
36
Perspective on malignant pleural mesothelioma diagnosis and treatment. ( 27127773 )
2016
37
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. ( 27903668 )
2016
38
KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. ( 27245839 )
2016
39
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. ( 27543082 )
2016
40
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. ( 26980049 )
2016
41
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro. ( 27512118 )
2016
42
210P: Digital gene expression profiling to separate malignant pleural mesothelioma from benign reactive mesothelial hyperplasia. ( 27198346 )
2016
43
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? ( 27597274 )
2016
44
The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma. ( 26440572 )
2016
45
Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Novel Mini-Invasive Technique. ( 27926627 )
2016
46
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis. ( 27198347 )
2016
47
Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma. ( 27091358 )
2016
48
A pilot study of volumetric-modulated arc therapy for malignant pleural mesothelioma. ( 27074478 )
2016
49
Functional Analysis of the Adrenomedullin Pathway in Malignant Pleural Mesothelioma. ( 26762744 )
2016
50
Biphasic Malignant Pleural Mesothelioma Masquerading as a Primary Skeletal Tumor. ( 27660729 )
2016

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

7 (show all 35)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13406 1 1 2300000 Loss Pleural malignant mesothelioma
2 21839 1 16200000 28000000 Loss Pleural malignant mesothelioma
3 33951 1 50700000 61300000 Amplification Pleural malignant mesothelioma
4 35953 1 69700000 116100000 Loss Pleural malignant mesothelioma
5 35955 1 69700000 116100000 Loss CLCA1 Pleural malignant mesothelioma
6 35957 1 69700000 116100000 Loss CLCA2 Pleural malignant mesothelioma
7 35959 1 69700000 116100000 Loss CLCA3 Pleural malignant mesothelioma
8 35961 1 69700000 116100000 Loss CLCA4 Pleural malignant mesothelioma
9 35963 1 69700000 116100000 Loss COL11A1 Pleural malignant mesothelioma
10 35965 1 69700000 116100000 Loss TGFBR3 Pleural malignant mesothelioma
11 35967 1 69700000 120600000 Loss Pleural malignant mesothelioma
12 37057 1 84900000 107200000 Loss Pleural malignant mesothelioma
13 69953 12 56600000 58100000 Gain Pleural malignant mesothelioma
14 75173 13 17900000 45800000 Loss BRCA2 Pleural malignant mesothelioma
15 85739 14 50900000 107349540 Loss CCNK Pleural malignant mesothelioma
16 85741 14 50900000 107349540 Loss CDKN3 Pleural malignant mesothelioma
17 113646 17 44900000 81195210 Gain ERN1 Pleural malignant mesothelioma
18 113648 17 44900000 81195210 Gain MAP3K3 Pleural malignant mesothelioma
19 113650 17 44900000 81195210 Gain PRKCA Pleural malignant mesothelioma
20 113652 17 44900000 81195210 Gain SMARCD2 Pleural malignant mesothelioma
21 175423 3 39400000 63700000 Loss CACNA2D3 Pleural malignant mesothelioma
22 175425 3 39400000 63700000 Loss CTNNB1 Pleural malignant mesothelioma
23 175427 3 39400000 63700000 Loss MLH1 Pleural malignant mesothelioma
24 175772 3 44100000 44200000 Loss Pleural malignant mesothelioma
25 187515 4 50400000 191154276 Loss Pleural malignant mesothelioma
26 191706 5 1 48400000 Gain Pleural malignant mesothelioma
27 204730 6 114600000 118300000 Loss HDAC2 Pleural malignant mesothelioma
28 204732 6 114600000 118300000 Loss MARCKS Pleural malignant mesothelioma
29 217076 7 1 4500000 Gain Pleural malignant mesothelioma
30 234872 8 139900000 146364022 Gain Pleural malignant mesothelioma
31 250027 9 19900000 25600000 Loss C9orf14 Pleural malignant mesothelioma
32 250030 9 19900000 25600000 Loss CDKN2A Pleural malignant mesothelioma
33 250032 9 19900000 25600000 Loss CDKN2B Pleural malignant mesothelioma
34 250070 9 19900000 33200000 Loss Pleural malignant mesothelioma
35 251885 9 33200000 36300000 Gain Pleural malignant mesothelioma

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for Malignant Pleural Mesothelioma

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 12.15 BIRC5 CDKN2A EGFR MET XIAP
2 11.48 BAP1 CDH2 SPP1
3 11.3 BIRC5 CDKN2A XIAP
4 10.83 CDH2 EGFR TXN
5 10.47 CDH2 MET SPP1

GO Terms for Malignant Pleural Mesothelioma

Biological processes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.62 BIRC5 EGFR WT1 XIAP
2 lung development GO:0030324 9.54 EGFR NKX2-1 PDPN
3 positive regulation of bone resorption GO:0045780 9.4 EGFR SPP1
4 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.26 PPP1R15A TXN
5 cerebral cortex cell migration GO:0021795 9.16 EGFR NKX2-1
6 cell proliferation GO:0008283 9.02 EGFR MET PDPN TXN TYMS
7 inhibition of cysteine-type endopeptidase activity involved in apoptotic process GO:1990001 8.96 BIRC5 XIAP

Molecular functions related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 8.92 CDH2 EGFR MET PPP1R15A

Sources for Malignant Pleural Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....